Research programme: stem cell therapeutics for lung disorders - APstem Therapeutics
Latest Information Update: 18 Jan 2022
Price :
$50 *
At a glance
- Originator APstem Therapeutics
- Class
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Adult respiratory distress syndrome; Chronic obstructive pulmonary disease
Most Recent Events
- 03 Jan 2022 APstem Therapeutics in-licenses adult pluripotent stem cell (APSC™) technology from Stanford University worldwide (APstem Therapeutics pipeline, January 2022)
- 03 Jan 2022 Early research in Adult respiratory distress syndrome in USA (Parenteral) (APstem Therapeutics pipeline, January 2022)
- 03 Jan 2022 Early research in Chronic obstructive pulmonary disease in USA (Parenteral) (APstem Therapeutics pipeline, January 2022)